Oral anti-pseudomonal antibiotics for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Remmington, Tracey ^a   Jahnke, Nikki ^a   Harkensee, Christian ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; BODY WEIGHT; BRONCHOSPASM; CANDIDIASIS; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GROWTH RATE; HEARING IMPAIRMENT; HUMAN; KIDNEY FAILURE; LONG TERM CARE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; VOMITING; ADULT; CHILD; COMPLICATION; META ANALYSIS; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84899469310     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005405.pub3     Document Type: Review

References (113)

1. Hodson ME, Roberts CM, Butland RJA, Batten JC. Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 1987;3(2):126.
2. Hodson ME, Roberts CM, Butland RJA, Batten JC. Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF) [abstract]. Proceedings of the 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1-2 September 1986; Budapest. 1986:20.
3. Hodson ME, Roberts CM, Butland RJA, Smith MJ. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1(8527):235-7.
4. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatric Infectious Disease Journal 1997;16(6):572-8.
5. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatric Infectious Disease Journal 1997;16(6):106-11.
6. Assoufi BK, Sheldon CD, Hodson ME. Double blind comparison of regular 3 monthly treatment with ciprofloxacin or placebo in cystic fibrosis patients who are chronically colonised with Pseudmonas aeruginosa [abstract]. Pediatric Pulmonology 1990;Suppl 5:204.
7. Assoufi BK, Sheldon CD, Hodson ME. Double blind comparison of regular three monthly treatment with ciprofloxacin or placebo in cystic fibrosis (CF) patients who are chronically colonised with Pseudmonas aeruginosa [abstract]. 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia. 1989:32.
8. Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respiratory Medicine 1993;87:587-93.
9. Wang CI, Inderlied CB, Armer C, Roldan MA, Osher AB. Comparison of the efficacy and safety of oral ciprofloxacin with that of i.v. tobramycin plus azlocillin and/or tobramycin plus ticarcillin in patients with cystic fibrosis [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)19.
10. Anstead M, Kuhn RJ, Halsey S, Doherty DE, D'Souza N, Kanga JF. Effect of azithromycin on lung function, sputum bacteriology, and sputum inflammatory markers in cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Suppl):A565.
11. Black A, Redmond A, Scott E. Randomised study comparing courses or oral ciprofloxacin alone with intermittent courses of intravenous azlocillin plus tobramycin or oral ciprofloxacin in the treatment of acute exacerbations of respiratory infection in cystic fibrosis [abstract]. Proceedings of the 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia. 1989:31.
12. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. Journal of Antimicrobial Chemotherapy 1990;26(Suppl F):25-9.
13. Black A, Stevenson M, Scott E, Redmond A. Randomised study comparing oral ciprofloxacin alone with ciprofloxacin alternating with intravenous therapy in cystic fibrosis [abstract]. Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:80.
14. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):180-4.
15. Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. American Journal of Medicine 1989;87(Suppl 5a):123s-7s.
16. Cipolli M, Cazzola G, Novelli A, Cassetta MI, Fallani S, Mazzeri T. Azithromycin concentrations in serum bronchial secretions of patients with cystic fibrosis. Clinical Drug Investigation 2001;21(5):353-60.
17. Davies RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, et al.Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(6):915-9.
18. Denning CR, Park S, Grece CA, Mellin GW. Continuous vs intermittent oral antibiotics in the management of patients with cystic fibrosis [abstract]. Proceedings of the 18th Annual Meeting Cystic Fibrosis Club Abstracts; 1977. 1977:23.
19. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360(9338):978-84.
20. Equi A, Bush A, Alton EW, Balfour-Lynn I, Rosenthsal M. A prospective double-blind randomised placebo controlled crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology 2001;Suppl 22:307.
21. Equi A, Bush A, Balfour-Lynn IM, Rosenthsal M. A prospective double-blind randomised placebo controlled crossover trial of azithromycin in paediatric cystic fibrosis [abstract]. Thorax 2002;57(Suppl iii):38.
22. Frederiksen B, Hansen A, Koch C, Hoiby N. Delay of recurrence of Pseudomonas aeruginosa in patients with cystic fibrosis with inhaled colistin and oral ciprofloxacin: a comparison between 3 weeks and 3 months of treatment [abstract]. Pediatric Pulmonology 1997;23 Suppl 14:288, Abstract no: 298. [CFGD Register: PI118a]
23. Frederiksen B, Pressler T, Koch C, Hoiby N. Endpoints for evaluating early anti-pseudomonal treatment: changes in pseudomonas prevalence and in pulmonary function [abstract]. Pediatric Pulmonology 2003;36 Suppl 25:334. [CFGD Register: PI118b; CRS-ID: 5500100000002399]
24. Goldfarb J, Wormser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, et al.Single dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 1986;26:222-6.
25. Harrison CJ, Marks MI, Welch DF, Sharma BB, Baker D, Dice J, et al.A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis. Pediatric Pharmacology 1985;5(1):7-16.
26. Jensen T, Pedersen SS, Høiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987;6(6):618-22.
27. Jensen T, Pedersen SS, Nielsen CH, Hoiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1987;20(4):585-94.
28. Pedersen SS, Jensen T, Hvidberg EF. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1987;20(4):575-83.
29. Johansen HK, Børch K, Espersen F, Koch C, Høiby N. Pivmecillinam + pivampicillin vs. pivampicillin in cystic fibrosis patients with Haemophilus influenzae infection [abstract]. Proceedings of 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:89.
30. Johansen HK, Børch K, Espersen F, Koch C, Høiby N. Randomised trial of pivampicillin plus pivmecillinam vs. pivampicillin in children and youg adults with chronic obstructive pulmonary disease and infection with Haemophilus influenzae. Current Medical Research and Opinion 1999;15(4):300-9.
31. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P19.
32. Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with Pseudomonas in their sputum. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:52.
33. Kurz CC, Marget W, Harms K, Bertele RM. A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally [Kreuzstudie über die Wirksamkeit von Ofloxacin und Cirpofolxacin bei oraler Anwendung]. Infection 1986;14(Suppl 1):S82-S86.
34. Kurz CC, Marget W, Harms K, Bertele RM. Comparison of ciprofloxacin and ofloxacin in cystic fibrosis: a cross-over study [Vergleichende Untersuchung mit Ciprofloxacin und Ofloxacin im Kreuzversuch bei zystischer Fibrose]. Fortschritte der Antimikrobiellen u. Antineoplastischen Chemotherapie 1987;6:2107-13.
35. Loening-Baucke V, Mischler EH, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics 1979;95(4):630-7.
36. Loening-Baucke V, Mischler EH, Myers MG. Cephalexin compared to placebo in the management of patients with cystic fibrosis [abstract]. Cystic Fibrosis Club Abstracts. 1978:69.
37. Loening-Baucke V, Mischler EH, Myers MG. Cephalexin in cystic fibrosis: a placebo-controlled study [abstract]. Pediatric Research 1978;12(4 Pt 2):495.
38. Mack G, Cooper PJ, Buchannan N. Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1991;35(7):1484-5.
39. Nolan G, McIvor P, Levison H, Fleming PC, Corey M, Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. Journal of Pediatrics 1982;101(4):626-30.
40. Ordonex CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis. Pediatric Pulmonology 2001;32(1):29-37.
41. Owen G, West J, Macguire S, Riley H, Goodchild M, Weller P. Continuous and intermittent antibiotic therapy in CF patients to age four years [abstract]. Proceedings of 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:95.
42. West J, Smith AW, Brown MRW, Weller PH. The longitudinal relationship between clinical status lung infection and immune responses in young cystic fibrosis patients [abstract]. Pediatric Pulmonology 1990;Suppl 5:222.
43. Williams J, Alfaham M, Riley HC, Goodchild MC, Weller PH, Dodge JA. Screening for cystic fibrosis in Wales and the West Midlands. 2: Clinical Evaluation [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:G(b)3.
44. Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. Journal of Cystic Fibrosis 2006; Vol. 5, issue 3:153-7. [MEDLINE: 96296083]
45. Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]. Pedaitric Pulmonology 1999;28(Suppl 19):263.
46. Postnikov SS, Semykin SJ, Najimov VP. Safety of fluoroquinolones in children [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P213.
47. Postnikov SS, Yu S, Semykin V, Nazhimov P, Kapranov NI. Comparative growth rate of a year at the children with mucoviscidosis treated and not treated with Ciprofloxacin: clinicomorphological comparisons. Antibiotiki I Khimioterapiia 2001;46(10):11-3.
48. Pukhalsky AL, Shmarina GV, Kapranov NI, Kashirskaja NJ, Kokarovtseva SN, Shabalova LA, et al.Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;Suppl 22:274.
49. Romano L, Girosi D, Spallone E, Parisi F, Minicucci L, Romano C. The use of ofloxacin in cystic fibrosis patients [Uso dell'ofloxacin nei pazienti con fibrosi cistica]. Minerva Pediatrica 1992;44(3):79-86.
50. Romano L, Minicucci L, Spallone E, Girosi D, Campelli A, Fabbri A, et al.Role of home therapy with ofloxacin in patients with cystic fibrosis (CF) [Ruolo della terapia domiciliare conofloxacin in pazienti con fibrosi cistica]. Giornale italiano di chemioterapia 1991;38(1-3):181-3.
51. Rubio TT. Ciprofloxacin: comparative data in cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):185-8.
52. Nguyen D, Mayor-Hamblett N, Marshall BC, Saiman L, Burns JL. Phenotypic characterization of Pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):286.
53. Saiman L. What have we learned from further analysis of the U.S. macrolide trial? Subgroup analysis of azithromycin trial. Pediatric Pulmonology 2003;Suppl 25:165-7.
54. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al.Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-56.
55. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2005;172(8):1008-12.
56. Scully BE, Nakatomi M, Ores C, Davidson S, Neu HC. Ciprofloxacin therapy in cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):196-201.
57. Shapera RM, Warwick WJ, Matsen JM. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. Journal of Pediatrics 1981;99(4):647-50.
58. Smith A, Weber A, Pandher R, Williams-Warren J, Cohen ML, Ramsey B. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 1997;25(2):106-8.
59. Sriram S, Young J, Waterhouse JC, Bucknall CE, Stack BHR. The antiinflammatory effect of clarithromycin in CF [abstract]. Journal of Cystic Fibrosis 2003;2(Suppl 1):S52.
60. Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, et al.Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 1992;36(11):2512-7.
61. Strandvik B, Hjelte L, Lindblad A, Ljungberg B, Malmborg AS, Nilsson-Ehle I. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scandinavian Journal of Infectious Diseases. Supplementum 1989;60:84-8.
62. Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):189-95.
63. Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hilman BC. Pharmacokinetics of two doses regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):142-5.
64. Anstead M, Lymp J, Khan U, Barbieri J, Langkamp M, Doring G, et al.Pseudomonas aeruginosa serology predicts response to treatment and re-infection in the EPIC clinical study [abstract]. Pediatric Pulmonology 2011;46(S34):303, Abstract no: 254. [CFGD Register: PI202g]
65. Hamblett NM, Retsch-Bogart GZ, Treggiari M, Kronmal RA, Khan U, Williams J, et al.Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study [abstract]. Pediatric Pulmonology 2009;44(S32):183. [CFGD CF Register: PI202b; MEDLINE: 96296083]
66. Hoffman LR, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Wolter DJ, Pope CE, et al.Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial [abstract]. Pediatric Pulmonology 2012;47(S35):317, Abstract no: 266. [CFGD Register: PI202j]
67. Khan U, Mayer-Hamblett N, Retsch-Bogart G, Treggiari M, Ramsey B. Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants & prior antibiotic exposure [abstract]. Pediatric Pulmonology 2010;45(S33):335, Abstract no: 326. [CFGD Register: PI202f]
68. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, et al.Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology 2012;47(2):125-34. [CFGD Register: PI202i]
69. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, et al.Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonlogy 2012;47(2):125-34. [DOI: 10.1002/ppul.21525]
70. Ramsey B. TOBI use in infants and children with early Pseudomonas Aeruginosa infection - duration of effect and epic update [abstract]. Pediatric Pulmonology 2005;40(S28):146. [CFGD CF Register: PI202a]
71. Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kronmal R, Ramsey B, et al.Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S54, Abstract no: 209. [CFGD Register: PI202e]
72. Treggiari M, Retsch-Bogart GZ, Mayer-Hamblett N, Kronmal R, Khan U, Williams J, et al.Early anti-pseudomonal infection in children with CF: study population and conduct of the "EPIC" clinical trial [abstract]. Pediatric Pulmonology 2009;44(S32):316, Abstract no: 299. [CFGD CF Register: PI202c; MEDLINE: 96296083]
73. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al.Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Pediatrics and Adolescent Medicine 2011;165(9):847-56. [CFGD Register: PI202h]
74. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, et al.Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contempory Clinical Trials 2009;30(3):256-68. [CFGD CF Register: PI202d; MEDLINE: 96296083]
75. Vitti TG, Berg TJ, Pagtakhan BS, Pagtakhan RD. The effect of pancreatic enzyme supplement on the intestinal absorption of ampicillin and cloxacillin in children with cystic fibrosis [abstract]. Proceedings of the 16th Annual Meeting Cystic Fibrosis Club Abstracts; 1975. 1975:56.
76. Beardsmore CS, Thompson JR, Williams A, McArdle EK, Gregory GA, Weaver LT, et al.Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Archives of Disease in Childhood 1994;71(2):133-7.
77. Weaver LT, Green MR, Nicholson K, Heeley ME, Mills J, Kuzemko JA. Continuous prophylactic flucloxacillin improves outcome of infants with cystic fibrosis (CF) detected soon after birth [abstract]. Proceedings of 63rd Annual Meeting of the British Paediatric Association; Warwick, UK; 1991. 1991:24.
78. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, et al.Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Archives of Disease in Childhood 1994;70(2):84-9.
79. Bell SC, Seeney S, Walmsley K, Wolter JM, Bowler SD, McCormack JG. Long term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis [abstract]. Pediatric Pulmonology 2002;Suppl 24:289-90.
80. Bowler SD. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics 2003;56(Suppl A):38.
81. Bowler SD, Masel PJ, Bell SC, Seeney SL, Wolter JM, McCormack JG. A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology. 2000; Vol. Suppl 20:280.
82. Bowler SD, Seeney S, Walmsley K, Wolter JM, Bell SC, McCormack JG. Long-term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis [abstract]. Respirology 2002;7(Suppl):A9.
83. Seeney SL, Bowler SD, Wolter JM, Bell SC, Masel PJ, McCormack JG. A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Internal Medicine Journal 2001;31(Suppl):A12.
84. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57(3):212-6.
85. Asensio O, Bosque M, Marco T, DeGracia J, Serra C. Home intravenous antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001917]
86. Ball P. Ciprofloxacin: an overview of adverse experiences. Journal of Antimicrobial Chemotherapy 1986;18(Suppl D):187-93.
87. Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. Journal of Antimicrobial Chemotherapy 1990;26(Suppl F):165-79.
88. Burns JL, Gibson R, McNamara S, Yim D, Emerson J, Rosenfeld M, et al.Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases 2001;183(3):444-52.
89. UK Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa infection in people with cystic fibrosis: Suggestions for prevention and infection control. Report of the UK Cystic Fibrosis Infection Control Group. 2nd edition 2004.
90. Cystic Fibrosis Foundation. Patient Registry Report. www.cff.org/research/ClinicalResearch/PatientRegistryReport/ (accessed 26 August 2010).
91. Döring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al.Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67.
92. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
93. FitzSimmons SC. The changing epidemiology of cystic fibrosis. Journal of Pediatrics 1993;122(1):1-9.
94. FitzSimmons SC. The Cystic Fibrosis Foundation Patient Registry Report 1996. Pediatric Pulmonology 1996;21(Suppl):267-75.
95. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
96. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51.
97. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
98. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al.Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatric Pulmonology 2001;32(4):277-87.
99. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. Journal of Cystic Fibrosis 2009;8(6):386-91.
100. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al.Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics 2001;138(5):699-704.
101. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infection & Immunity 1999;67(9):4744-50.
102. Patterson DR. Quinolone toxicity: methods of assessment. American Journal of Medicine 1991;91(6A):35S-37S.
103. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
104. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Seminars in Respiratory Infections 2002;17(1):47-56.
105. Ratjen F. Diagnosing and managing infection in CF. Paediatric Respiratory Review 2006;7(Suppl 1):S151-3.
106. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al.Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology 2001;32(5):356-66.
107. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children?. Pediatric Infectious Diseases Journal 2007;26(10):865-7.
108. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, et al.Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). European Journal of Obstetrics, Gynecology, and Reproductive Biology 1996;69(2):83-9.
109. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD002203.pub2]
110. Wang S, Fitzsimmons S, O'Leary L, Rock M, Gwinn M, Khoury M. Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa in the first 10 years of life: a registry-based longitudinal study. Pediatrics 2001;107(2):274-9.
111. West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al.Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287(22):2958-67.
112. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004197.pub2]
113. Remmington T, Jahnke N, Harkensee C. Oral anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD005405.pub2]